Hope or hype the obsession with medical advances and the high cost of false promises /

Enregistré dans:
Détails bibliographiques
Auteur principal: Deyo, Richard A.
Collectivité auteur: ebrary, Inc
Autres auteurs: Patrick, Donald L.
Format: Électronique eBook
Langue:anglais
Publié: New York : AMACOM, American Management Association, c2005.
Sujets:
Accès en ligne:An electronic book accessible through the World Wide Web; click to view
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

MARC

LEADER 00000nam a22000004a 4500
001 0000077396
005 20171002053856.0
006 m u
007 cr cn|||||||||
008 040922s2005 nyua sb 001 0 eng
010 |z  2004022295 
020 |z 0814408451 
035 |a (CaPaEBR)ebr10075614 
035 |a (OCoLC)614665643 
040 |a CaPaEBR  |c CaPaEBR 
050 1 4 |a RA418.5.M4  |b D49 2005eb 
082 0 4 |a 610/.28  |2 22 
100 1 |a Deyo, Richard A. 
245 1 0 |a Hope or hype  |h [electronic resource] :  |b the obsession with medical advances and the high cost of false promises /  |c Richard A. Deyo, Donald L. Patrick. 
260 |a New York :  |b AMACOM, American Management Association,  |c c2005. 
300 |a xvi, 335 p. :  |b ill. 
504 |a Includes bibliographical references (p. [291]-326) and index. 
505 0 |a Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 
505 0 |a Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from "experimental" to "standard care" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 
533 |a Electronic reproduction.  |b Palo Alto, Calif. :  |c ebrary,  |d 2013.  |n Available via World Wide Web.  |n Access may be limited to ebrary affiliated libraries. 
650 0 |a Medical innovations  |z United States  |x Evaluation. 
650 0 |a Medical technology  |z United States  |x Evaluation. 
650 0 |a Medical care  |x Technological innovations  |z United States  |x Evaluation. 
650 0 |a Medical care  |z United States  |x Evaluation. 
650 0 |a Medical innovations  |x Economic aspects  |z United States. 
650 0 |a Medical technology  |z United States  |x Cost effectiveness. 
650 0 |a Medical care  |x Technological innovations  |z United States  |x Cost effectiveness. 
650 0 |a Medical care, Cost of  |z United States. 
655 7 |a Electronic books.  |2 local 
700 1 |a Patrick, Donald L. 
710 2 |a ebrary, Inc. 
856 4 0 |u http://site.ebrary.com/lib/daystar/Doc?id=10075614  |z An electronic book accessible through the World Wide Web; click to view 
908 |a 170314 
942 0 0 |c EB 
999 |c 66554  |d 66554